

NANOMATERIALS IN PERSONALIZED MEDICINE: GLOBAL MARKETS



HLC144A
July 2013

Alessandro Varotto
Project Analyst

ISBN: 1-56965-441-7

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVE	2
REASON FOR DOING THE STUDY	2
SCOPE OF THE REPORT	2
INTENDED AUDIENCE	3
METHODOLOGY AND INFORMATION SOURCE	3
ANALYST CREDENTIALS	4
RELATED REPORTS	4
BCC ON-LINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL NANOMATERIAL FOR PERSONALIZED MEDICINE MARKET, THROUGH 2017 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL NANOMATERIAL FOR PERSONALIZED MEDICINE MARKET, 2011-2017 (\$ MILLIONS)</i>	6
CHAPTER 3 OVERVIEW	9
THERANOSTICS AND PERSONALIZED MEDICINE OVERVIEW	9
<i>TABLE 1 THERAPIES WITH DIAGNOSTIC COMPANION KITS</i>	10
<i>FIGURE 1 RISK OF CANCER FOR PATIENTS THAT CARRY A SPECIFIC GENETIC MUTATION VS NON MUTATED (%)</i>	11
NANOPARTICLES	14
PASSIVE TARGETING	15
ACTIVE TARGETING	15
NANOTECHNOLOGY OVERVIEW	16
NANOTECHNOLOGY PRODUCTS ON THE MARKET	17
SIZE DEFINITION	17
SHAPE	17
SURFACE AREA	18
QUANTUM DOTS	18
CARBON NANOTUBES	18
MULTIFUNCTIONAL NANOMATERIALS	18
<i>TABLE 2 NANOMATERIAL TYPES</i>	19
NANOTHERANOSTICS OVERVIEW	20
<i>TABLE 3 MAJOR PLAYERS IN THE NANOPARTICLE DRUG FIELD</i>	21
<i>TABLE 4 NANOPARTICLE DRUG MARKET BY COMPANY, THROUGH 2017 (\$ MILLIONS)</i>	21
GOLD-BASED NANOMATERIALS	22
MAGNETIC NANOMATERIALS	22
POLYMERIC NANOMATERIALS	24
SILICA-BASED NANOMATERIALS	24
CARBON NANOMATERIALS	25
COMPOSITE NANOMATERIALS	25
BIOLOGIC NANOMATERIALS: ANTIBODY, PROTEINS AND DNA	25
OTHER NANOMATERIALS	26

TOPIC	PAGE NO.
DRUG DELIVERY	26
TABLE 5 MAJOR NANOMATERIAL APPLICATIONS IN PERSONALIZED MEDICINE	27
CHAPTER 4 GLOBAL NANOMATERIAL FOR PERSONALIZED MEDICINE MARKET	29
TABLE 6 GLOBAL NANOMATERIAL PERSONALIZED MEDICINE MARKET, THROUGH 2017 (\$ MILLIONS)	29
FIGURE 2 GLOBAL NANOMATERIAL FOR PERSONALIZED MEDICINE MARKET, 2011-2017 (\$ MILLIONS)	30
GLOBAL MONOCLONAL ANTIBODIES FOR PERSONALIZED MEDICINE MARKET	30
TABLE 7 GLOBAL MONOCLONAL ANTIBODY MARKET, THROUGH 2017 (\$ MILLIONS)	30
TABLE 8 GLOBAL PROTEIN MARKET, THROUGH 2017 (\$ MILLIONS)	30
GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTICS IMAGING SYSTEMS	31
TABLE 9 GLOBAL DIAGNOSTIC IMAGING AND TESTING NANOPARTICLE MARKET, THROUGH 2017 (\$ MILLIONS)	31
GLOBAL REVENUES FOR DRUG DEVELOPMENT AND FORMULATION	32
TABLE 10 GLOBAL DRUG-DEVELOPMENT AND FORMULATION NANOPARTICLE MARKET, THROUGH 2017 (\$ MILLIONS)	32
GLOBAL MAGNETIC RESONANCE IMAGING REAGENT MARKET	32
TABLE 11 GLOBAL IRON-OXIDE NANOPARTICLES USED AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS MARKET, THROUGH 2017 (\$ MILLIONS)	32
GLOBAL IN VITRO OPTICAL IMAGING REAGENT MARKET	33
TABLE 12 GLOBAL NANOMATERIALS USED AS IN VITRO OPTICAL IMAGING REAGENTS MARKET, THROUGH 2017 (\$ MILLIONS)	33
GLOBAL GOLD-BASED MATERIALS USED AS NANOCARRIERS MARKET	33
TABLE 13 GLOBAL GOLD-BASED NANOMATERIALS USED AS CARRIERS MARKET, THROUGH 2017 (\$ MILLIONS)	33
GLOBAL LIPOSOMAL-BASED MATERIALS USED AS NANOCARRIERS MARKET	34
TABLE 14 GLOBAL LIPOSOME-BASED MATERIALS USED AS DRUG CARRIERS MARKET, THROUGH 2017 (\$ MILLIONS)	34
GLOBAL NANOCRYSTAL DRUG MARKET	34
TABLE 15 GLOBAL NANOCRYSTAL DRUG MARKET, THROUGH 2017 (\$ MILLIONS)	34
GLOBAL BLOCKBUSTER ANTIBODY DRUG MARKET	35
TABLE 16 GLOBAL MONOCLONAL ANTIBODY BLOCKBUSTER DRUG MARKET, THROUGH 2017 (\$ MILLIONS)	35
CHAPTER 5 NANOTHERANOSTIC DRUG DELIVERY	37
INTRODUCTION	37
IN VIVO DRUG RELEASE STUDIES	38
DRUG EFFICACY	39
FUTURE DIRECTIONS	40
TABLE 17 EXAMPLES OF NANOMATERIALS USED IN THERANOSTICS	40
TABLE 18 IMAGING MODALITIES USED IN THERANOSTIC NANODEVICES	40
CHAPTER 6 NANOMATERIAL STRUCTURES, CHARACTERISTICS AND METHODS OF PREPARATION	43
CARBON NANOTUBES	43
CARBON NANOTUBES AS CARRIERS OF IMMUNOACTIVE COMPOUNDS, PROTEINS AND GENETIC MATERIALS	44
CANCER PHOTOTHERMAL THERAPY	45
CARBON NANOTUBES FOR OTHER THERAPEUTIC APPLICATIONS	45

TOPIC	PAGE NO.
FULLERENE C60	45
C60 TOXICITY	46
UPTAKE AND BIODISTRIBUTION	46
ANTIOXIDANT PROPERTIES	46
ENDOHEDRALS	47
MAGNETIC RESONANCE IMAGING	47
RADIONUCLIDES	48
PHOTODYNAMIC THERAPY	48
DNA PHOTOCLEAVAGE	48
CANCER	49
INHIBITION OF ENZYMES, VIRUSES AND BACTERIA	50
DRUG AND GENE DELIVERY	50
PROTEINS	51
ENZYMES	52
TABLE 19 NON-MONOCLONAL ANTIBODY PROTEINS	52
MONOCLONAL ANTIBODIES	53
TABLE 20 MAJOR PLAYERS IN THE MONOCLONAL ANTIBODY MARKET	53
MONOCLONAL ANTIBODY THERAPY	54
TABLE 21 GLOBAL MONOCLONAL ANTIBODY MARKET	54
Mechanisms	55
NANOMATERIALS IN PERSONALIZED MEDICINE	56
TABLE 22 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT	56
TABLE 23 NANOPARTICLE DRUG MARKET BY PRODUCT, THROUGH 2017	57
GOLD NANOPARTICLES	58
GOLD NANOCARRIERS	58
HYPERTHERMIA	59
CONTRAST ENHANCERS	59
RADIOTHERAPY	59
TABLE 24 U.S. FOOD AND DRUG ADMINISTRATION-APPROVED NANOPARTICLE DRUG-DELIVERY SYSTEMS	60
MAGNETIC NANOPARTICLES	62
HYPERTHERMIA	63
MAGNETIC SEPARATION	64
IMAGING AND DELIVERY	64
BRAIN TUMOR DELIVERY	65
PROSTATE CANCER	65
BLADDER TUMOR	65
LIPOSOMES	66
TABLE 25 LIPOSOME ADVANTAGES	67
LIPOSOME CLASSIFICATION AND PREPARATION	67
Sonication	68
Extrusion	68
Freeze-Thawed Liposomes	68
Solvent Dispersion Method	69
Detergent-Removal Method	70
STEALTH LIPOSOME	70
ANTIBODY-LIPOSOME CONJUGATE	71
Liposome Application in Medicine and Pharmacology	71

TOPIC	PAGE NO.
Liposomes in Parasitic Diseases and Infections	72
Liposomes in Anti-Cancer Therapies	72
<i>TABLE 26 LIPOSOME-BASED DRUGS</i>	73
<i>TABLE 27 MAJOR PLAYERS IN THE LIPOSOME MARKET</i>	74
NANOCRYSTALS	74
<i>TABLE 28 NANOCRYSTAL PROPERTIES</i>	75
<i>TABLE 29 NANOCRYSTAL DRUG FEATURES</i>	76
NANOCRYSTALS FABRICATION	76
<i>TABLE 29 NANOCRYSTAL DRUG FEATURES</i>	76
Precipitation Methods	76
Milling	77
Homogenization Method	77
<i>TABLE 30 NANOCRYSTAL MANUFACTURING TECHNOLOGIES</i>	77
<i>TABLE 31 NANOCRYSTAL DRUGS CURRENTLY ON THE MARKET</i>	77
QUANTUM DOTS	78
QUANTUM DOTS NANOCARRIER	78
PHOTOPHYSICAL PROPERTIES: DRUG-DELIVERY AND DRUG-RELEASE SENSING	79
Visualizing Intracellular Uptake In Vitro	80
Nanocarrier Biodistribution In Vivo	81
Short Interfering RNA and DNA delivery	81
MULTIFUNCTIONAL NANOPARTICLES	82
POLYMERIC NANOPARTICLES IN CANCER THERAPY	82
Polymer-Based Imaging Probes for Cancer Imaging	83
QUANTUM DOTS IN CANCER IMAGING AND THERAPY	84
QUANTUM DOTS IN PHOTODYNAMIC THERAPY AND IMAGING	84
MULTIFUNCTIONAL MAGNETIC NANOPARTICLES FOR CANCER IMAGING AND THERAPY	84
MAGNETIC NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING AND GENE DELIVERY	85
MULTIFUNCTIONAL MAGNETO-POLYMERIC NANOHYBRIDS FOR CANCER IMAGING AND THERAPY	85
GOLD NANOMATERIALS FOR PHOTOTHERMAL THERAPY	85
GOLD NANOSHELLS	85
GOLD NANORODS	86
MAGNETIC GOLD NANOSHELLS FOR PHOTOTHERMAL THERAPY AND IMAGING	86
CHAPTER 7 NANODEVICES AND NANOMATERIALS FOR DIAGNOSTICS	88
OVERVIEW	88
MOLECULAR RECOGNITION IN DIAGNOSIS	88
NANOPATTERNED DEVICES	89
PARTICLES	91
Magnetic Nanoparticles	91
Quantum Dots	91
Aptamer-Conjugated Nanoparticles	92
Nanoparticle-Based Bio-Bar Codes	92
Multiplex Dendrimers	92
Surface Enhanced Raman Spectroscopy	93

TOPIC	PAGE NO.
DIAGNOSTIC AND MEDICAL DEVICE INDUSTRY	93
CONCLUSIONS AND FUTURE TRENDS	93
<i>TABLE 32 KEY PLAYERS IN THE IN VITRO DIAGNOSTIC MARKET</i>	94
<i>TABLE 33 KEY PLAYERS IN THE DIAGNOSTIC IMAGING MARKET</i>	95
CHAPTER 8 NANOMATERIAL-BASED TREATMENTS FOR INFECTIONS ASSOCIATED WITH MEDICAL DEVICES	97
INFECTIONS ASSOCIATED WITH MEDICAL DEVICES AND THEIR TREATMENTS	97
CATHETER-ASSOCIATED INFECTIONS	97
SOFT-TISSUE-IMPLANT-ASSOCIATED INFECTIONS	97
BIOFILM FORMATION	97
COMMON METHODS FOR PREVENTING AND TREATING MEDICAL DEVICE-ASSOCIATED INFECTIONS	98
NANOMATERIALS IN MEDICAL APPLICATIONS	98
Antimicrobial Nanomaterials	98
Silver Nanoparticles	98
Zinc Oxide	99
Iron and Iron-Oxide Nanoparticles	99
Titanium Oxide	99
Carbon Nanotubes and Fullerenes	100
Chitosans	100
CYTOTOXICITY CONSIDERATION	101
CHAPTER 9 PERSONALIZED MEDICINE REGULATORY FRAMEWORKS	103
OVERVIEW	103
NANOPRODUCT PHYSICOCHEMICAL PROPERTY DIFFERENCES COMPARED TO THEIR LARGER COUNTERPARTS	104
REGULATORY ISSUES IN NANOTECHNOLOGY	105
CHAPTER 10 COMPETITIVE ANALYSIS	108
INTRODUCTION	108
CONTRACT MANUFACTURING ORGANIZATIONS	109
INFORMATION TECHNOLOGY	109
ONCOLOGY	110
<i>TABLE 34 GLOBAL BLOCKBUSTER MONOCLONAL ANTIBODIES IN THE ONCOLOGY MARKET, THROUGH 2017 (\$ MILLIONS)</i>	111
<i>TABLE 35 BLOCKBUSTER MONOCLONAL ANTIBODY PATENT EXPIRATION</i>	111
BIOSIMILARS VERSUS GENERICS	111
Biosimilar: Competition and Improvement	113
ANTIRHEUMATICS MARKET	114
<i>TABLE 36 BLOCKBUSTER MONOCLONAL ANTIBODIES FOR THE ANTIRHEUMATIC MARKET, THROUGH 2017</i>	114
EMERGING MARKETS	115
<i>TABLE 37 KEY PLAYERS IN THE GENERIC MARKET</i>	116
<i>TABLE 38 COMPANY EVENTS IMPACTING THE THERANOSTIC MARKET</i>	116
CHAPTER 11 COMPANY PIPELINES	132
<i>TABLE 39 PROTEIN DRUGS</i>	132

TOPIC	PAGE NO.
<i>TABLE 40 NANOPARTICLES DRUGS</i>	133
CHAPTER 12 THERAPY AND DIAGNOSTICS COMPANION KITS	135
CHAPTER 13 PATENT STATUS	139
<i>TABLE 41 PATENTS BY TECHNOLOGY, 2001-2012</i>	139
<i>TABLE 42 QUANTUM DOT PATENT ASSIGNMENTS BY COMPANY</i>	139
<i>TABLE 43 GOLD NANOPARTICLE PATENT ASSIGNMENTS BY COMPANY</i>	139
CHAPTER 14 DRIVERS AND LIMITERS	141
DRIVERS	141
<i>TABLE 44 PERSONALIZED MEDICINE MARKET DRIVERS</i>	141
LIMITERS	144
<i>TABLE 45 PERSONALIZED MEDICINE MARKET LIMITERS</i>	144
CHAPTER 15 COMPANY PROFILES	146
AFFYMETRIX	146
A.P. PHARMA INC.	146
ABRAXIS BIOSCIENCES INC.	146
PRODUCTS	147
ACUSPHERE INC.	147
PRODUCTS	147
STRATEGY	147
ACCUTHERANOSTICS	147
ADVANCED PROTEOME THERAPEUTICS INC.	148
ADVANCED RESEARCH TECHNOLOGIES INC.	148
PRODUCTS	149
STRATEGY	149
AFFIBODY AB	149
PRODUCTS	149
STRATEGY	149
AGENIX LTD.	149
PRODUCTS	150
STRATEGY	150
ALNYLAM PHARMACEUTICALS INC.	150
PRODUCTS	150
STRATEGY	150
ALSERES PHARMACEUTICALS INC.	150
PRODUCTS	151
STRATEGY	151
AMAG PHARMACEUTICALS INC.	151
PRODUCTS	152
STRATEGY	152
AMBRY GENETICS	152
APHIOS CORPORATION	152
PRODUCTS	153
STRATEGY	153

TOPIC	PAGE NO.
ALACRIS THERANOSTICS GMBH	153
ALZA CORP.	153
ARROWHEAD RESEARCH CORPORATION	154
PRIMARY OPPORTUNITIES	154
Improving Active Pharmaceutical Ingredients	154
Patient Population Enrichment Strategies	154
Improving Generics	155
LEAD PRODUCTS	155
PLATFORM TECHNOLOGIES	155
ASKLEPIOS BIOPHARMACEUTICAL INC.	155
PRODUCTS	156
STRATEGY	156
ASTELLA PAHRMA INC.	156
PRODUCTS	156
STRATEGY	156
ASTRAZENECA PHARMACEUTICALS PLC	157
PRODUCTS	157
STRATEGY	157
ATREUS PHARMACEUTICALS CORPORATION	157
PRODUCTS	157
STRATEGY	157
AXXAM SPA	158
BAYER HEALTHCARE AG	158
PRODUCTS	158
STRATEGY	158
BECKMAN COULTER	158
BIOMERIEUX	159
BIONKIT LTD.	160
BBI INTERNATIONAL	160
BIND BIOSCIENCES INC.	160
PRODUCTS	160
STRATEGY	161
BIOPAL	161
CERULEAN PHARMA INC.	161
PRODUCTS	161
STRATEGY	161
CYTIMMUNE	162
DEBIOTECH, S.A.	162
PRODUCTS	163
STRATEGY	163
ELAN PHARMACEUTICALS INC.	163
PRODUCTS	163
STRATEGY	163
EISAI	164
EPIGENOMICS AG	165
FLAMEL TECHNOLOGIES INC.	165
PRODUCTS	165

TOPIC	PAGE NO.
STRATEGY	166
FUJIFILM KYOWA KIRIN CO LTD.	166
GENOMIC HEALTH	166
GILEAD	166
GE GLOBAL RESEARCH	167
PRODUCTS	167
STRATEGY	167
GSK SMITHKLINE	168
INGEN BIOSCIENCES	168
INNOVA BIOSCIENCES	168
INSIGHT GENOMICS	168
IPSEN	169
IZON	169
JANSSEN BIOTECH INC.	169
JOHNSON & JOHNSON	170
LAB 21	170
LIQUIDIA TECHNOLOGIES INC.	171
MAGFORCE NANOTECHNOLOGIES AG	171
PRODUCTS	171
STRATEGY	172
MERCK	172
MONOGRAM BIOSCIENCES	172
NANOCS	172
NANOCARRIER CO. LTD.	173
PRODUCTS	173
STRATEGY	173
NANOCOMPOSIX	173
NANOPARTZ INC.	174
NANOPROBES INC.	174
NANOSPHERE INC.	174
PRODUCTS	174
STRATEGY	175
NANOSIGHT LTD.	175
NANOTHERAPEUTICS	175
NEKTAR	176
NOVARTIS INTERNATIONAL AG	176
PRODUCTS	176
STRATEGY	176
OCEAN NANOTECH	177
TECHNOLOGY	177
PACIFIC BIOMARKERS	178
PARTICLE SCIENCES	178
PFIZER	179
PHARNEXT	179
SANOFI	180
SELECTA BIOSCIENCE	180
SOLUBEST	181

TOPIC	PAGE NO.
SURMODICS INC.	182
SKYEPHARMA PLC	182
PRODUCTS	182
STRATEGY	182
STARPHARMA HOLDINGS LTD.	183
PRODUCTS	183
STRATEGY	183
T2 BIOSTEMS INC.	183
PRODUCTS	184
STRATEGY	184
TALON THERAPEUTICS INC.	184
PRODUCTS	184
STRATEGY	184
TAKEDA	184
THERANOSTIC HEALTH	185
PRECLINICAL BIOMARKER DISCOVERY	185
TRANSLATIONAL RESEARCH	185
PROTEOMIC TECHNOLOGIES	185
THERANOSTICS LAB LTD.	185

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL NANOMATERIAL FOR PERSONALIZED MEDICINE MARKET, THROUGH 2017 (\$ MILLIONS)	6
TABLE 1 THERAPIES WITH DIAGNOSTIC COMPANION KITS	10
TABLE 2 NANOMATERIAL TYPES	19
TABLE 3 MAJOR PLAYERS IN THE NANOPARTICLE DRUG FIELD	21
TABLE 4 NANOPARTICLE DRUG MARKET BY COMPANY, THROUGH 2017 (\$ MILLIONS)	21
TABLE 5 MAJOR NANOMATERIAL APPLICATIONS IN PERSONALIZED MEDICINE	27
TABLE 6 GLOBAL NANOMATERIAL PERSONALIZED MEDICINE MARKET, THROUGH 2017 (\$ MILLIONS)	29
TABLE 7 GLOBAL MONOCLONAL ANTIBODY MARKET, THROUGH 2017 (\$ MILLIONS)	30
TABLE 8 GLOBAL PROTEIN MARKET, THROUGH 2017 (\$ MILLIONS)	30
TABLE 9 GLOBAL DIAGNOSTIC IMAGING AND TESTING NANOPARTICLE MARKET, THROUGH 2017 (\$ MILLIONS)	31
TABLE 10 GLOBAL DRUG-DEVELOPMENT AND FORMULATION NANOPARTICLE MARKET, THROUGH 2017 (\$ MILLIONS)	32
TABLE 11 GLOBAL IRON-OXIDE NANOPARTICLES USED AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS MARKET, THROUGH 2017 (\$ MILLIONS)	32
TABLE 12 GLOBAL NANOMATERIALS USED AS IN VITRO OPTICAL IMAGING REAGENTS MARKET, THROUGH 2017 (\$ MILLIONS)	33
TABLE 13 GLOBAL GOLD-BASED NANOMATERIALS USED AS CARRIERS MARKET, THROUGH 2017 (\$ MILLIONS)	33
TABLE 14 GLOBAL LIPOSOME-BASED MATERIALS USED AS DRUG CARRIERS MARKET, THROUGH 2017 (\$ MILLIONS)	34
TABLE 15 GLOBAL NANOCRYSTAL DRUG MARKET, THROUGH 2017 (\$ MILLIONS)	34
TABLE 16 GLOBAL MONOCLONAL ANTIBODY BLOCKBUSTER DRUG MARKET, THROUGH 2017 (\$ MILLIONS)	35
TABLE 17 EXAMPLES OF NANOMATERIALS USED IN THERANOSTICS	40
TABLE 18 IMAGING MODALITIES USED IN THERANOSTIC NANODEVICES	40
TABLE 19 NON-MONOCLONAL ANTIBODY PROTEINS	52
TABLE 20 MAJOR PLAYERS IN THE MONOCLONAL ANTIBODY MARKET	53
TABLE 21 GLOBAL MONOCLONAL ANTIBODY MARKET	54
TABLE 22 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT	56
TABLE 23 NANOPARTICLE DRUG MARKET BY PRODUCT, THROUGH 2017	57
TABLE 24 U.S. FOOD AND DRUG ADMINISTRATION-APPROVED NANOPARTICLE DRUG-DELIVERY SYSTEMS	60
TABLE 25 LIPOSOME ADVANTAGES	67
TABLE 26 LIPOSOME-BASED DRUGS	73
TABLE 27 MAJOR PLAYERS IN THE LIPOSOME MARKET	74
TABLE 28 NANOCRYSTAL PROPERTIES	75
TABLE 29 NANOCRYSTAL DRUG FEATURES	76
TABLE 29 NANOCRYSTAL DRUG FEATURES	76
TABLE 30 NANOCRYSTAL MANUFACTURING TECHNOLOGIES	77
TABLE 31 NANOCRYSTAL DRUGS CURRENTLY ON THE MARKET	77
TABLE 32 KEY PLAYERS IN THE IN VITRO DIAGNOSTIC MARKET	94
TABLE 33 KEY PLAYERS IN THE DIAGNOSTIC IMAGING MARKET	95
TABLE 34 GLOBAL BLOCKBUSTER MONOCLONAL ANTIBODIES IN THE ONCOLOGY MARKET, THROUGH 2017 (\$ MILLIONS)	111
TABLE 35 BLOCKBUSTER MONOCLONAL ANTIBODY PATENT EXPIRATION	111

TABLE HEADING	PAGE NO.
TABLE 36 BLOCKBUSTER MONOCLONAL ANTIBODIES FOR THE ANTIRHEUMATIC MARKET, THROUGH 2017	114
TABLE 37 KEY PLAYERS IN THE GENERIC MARKET	116
TABLE 38 COMPANY EVENTS IMPACTING THE THERANOSTIC MARKET	116
TABLE 39 PROTEIN DRUGS	132
TABLE 40 NANOPARTICLES DRUGS	133
TABLE 41 PATENTS BY TECHNOLOGY, 2001-2012	139
TABLE 42 QUANTUM DOT PATENT ASSIGNMENTS BY COMPANY	139
TABLE 43 GOLD NANOPARTICLE PATENT ASSIGNMENTS BY COMPANY	139
TABLE 44 PERSONALIZED MEDICINE MARKET DRIVERS	141
TABLE 45 PERSONALIZED MEDICINE MARKET LIMITERS	144

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL NANOMATERIAL FOR PERSONALIZED MEDICINE MARKET, 2011-2017 (\$ MILLIONS)	6
FIGURE 1 RISK OF CANCER FOR PATIENTS THAT CARRY A SPECIFIC GENETIC MUTATION VS NON MUTATED (%)	11
FIGURE 2 GLOBAL NANOMATERIAL FOR PERSONALIZED MEDICINE MARKET, 2011-2017 (\$ MILLIONS)	30